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Abstract: Viral encephalitis causes acute inflammation of the brain parenchyma and is a significant
cause of human morbidity and mortality. Although Herpes Simplex encephalitis is the most frequent
known cause of fatal sporadic encephalitis in humans, an increasingly wide range of viruses and
other microbial pathogens are implicated. Up to 60% of cases of presumed viral encephalitis remain
unexplained due to the failure of conventional laboratory techniques to detect an infectious agent.
High-throughput DNA sequencing technologies have the potential to detect any microbial nucleic
acid present in a biological specimen without any prior knowledge of the target sequence. While
there remain challenges intrinsic to these technologies, they have great promise in virus discovery in
unexplained encephalitis.
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1. Introduction
Encephalitis refers to inflammation of the brain parenchyma that typically presents with a
combination of features including fever, headache, clouding of consciousness, seizures, personality
change, focal neurological deficits, and coma [1,2]. It is often accompanied by meningitis and
inflammation of the membranes that cover the brain and spinal cord. Encephalitis must always
be distinguished from an encephalopathy, which may present similarly but results from metabolic
disturbances caused by liver or renal failure, intoxications, systemic infections, or anoxia, rather than
from inflammation [2,3].
Forty to sixty percent of encephalitis cases are unexplained [1,2,4,5]. Encephalitis can be
caused by direct infection by microbial agents (bacteria, fungi, viruses, parasites) or can be
immune-mediated [1,3,6]. Immune-mediated encephalitis usually occurs as a result of a post-infectious
process such as acute disseminated encephalomyelitis (ADEM), typically following infection with
measles, mumps, or rubella virus infection [6,7], or, as has more recently been increasingly described,
due to antibody-mediated encephalitis such as those caused by antibodies to voltage-gated potassium
channels or to the N-methyl-D-aspartate (NMDA) receptor [8,9].
Viruses are an important, yet often poorly understood cause of encephalitis. A range of viral
agents have been implicated [10]. Herpes Simplex virus (HSV)-1 is the virus most commonly implicated
in fatal sporadic encephalitis; however, other viruses implicated in encephalitis include herpesviruses
(HSV-2, varicella-zoster, cytomegalovirus, Epstein-Barr, and HHV 6 and 7); paramyxoviruses (measles,
rubella); orthomyxoviruses (influenza A virus); enteroviruses (EV 70 and 71, polio-, echo- and
coxsackieviruses); flaviviruses (West Nile, Japanese encephalitis, dengue and Zika viruses); retroviruses
(human immunodeficiency virus); alphaviruses (Venezuelan equine-, eastern equine-, western
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equine-encephalitis); bunyaviruses (La Crosse virus); rhabdoviruses (rabies virus); parvovirus (B19);
and astroviruses [3,6,11].
2. Differential Diagnosis of Presumed Viral Encephalitis
The most relevant means of neurological identification of a causative agent in encephalitis is by
examination of the cerebrospinal fluid (CSF) or brain tissue obtained at either brain biopsy or autopsy.
Methods employed include virus isolation, polymerase chain reaction (PCR), immunohistochemistry
or electron microscopy, serology, and, more recently, high-throughput sequencing (HTS). Viral isolation
is the classical method for diagnosis, but it is increasingly used in concert with PCR, which has become
more accessible and can provide near immediate actionable data. Culture requires days to weeks and
may fail in the event that the virus cannot be propagated in the cell line selected, whereas PCR requires
only a few hours.
The role of CSF PCR in the diagnosis of viral infections of the nervous system has been extensively
reviewed [12]. While the specificity and sensitivity of some PCR assays such as that for HSV-1 DNA
are exceptionally high at 96% and 99% respectively, other assays are not as robust. For example, while
it was originally thought that PCR for central nervous system (CNS) enteroviral infections was very
sensitive at 95%, more recent data suggest that this figure may be considerably lower [12]. Because
of the various potential problems with PCR in neurovirological diagnosis, caution must be exercised
when basing the identification of novel CNS viruses with this technique alone.
Serology can succeed where both culture and PCR fail; however, diagnosis may require the
collection of samples at two different time points when IgM is negative, and cross-reactive antibodies
can confound specificity, as during the early phase of investigation during the 1999 West Nile virus
outbreak in North America when St. Louis encephalitis virus was inaccurately implicated [13,14].
Furthermore, elevated antiviral antibodies may simply represent nonspecific polyclonal activation of
memory B cells from a previous infection [15].
Diagnosis of an infection is best achieved by obtaining a specimen directly at the site of disease.
However, a brain biopsy is often a measure of last resort and, consequently, the specimen is rarely
available. When accessible, the scarce amount of tissue material available greatly restricts the number
of experiments that can be performed. In most cases, CSF is the only surrogate specimen available for
the assessment of CNS disorders.
In instances where CNS sampling is not possible or fails to provide clues to a causative agent,
some clinicians and investigator survey blood, the oropharynx, feces, or urine. The identification of an
agent in any sample type may lead to targeted assays of CSF or antibody tests, if seroconversion is
consistent with acute infection.
3. Viral Discovery
The advent of unbiased DNA sequencing technologies offers unprecedented opportunities to
detect unexpected, previously unrecognized, or novel microbial pathogens in undiagnosed encephalitis.
Unlike sequence-based methods that are limited to the detection of known or related agents, unbiased
high-throughput sequencing (HTS) has the potential to detect any microbial nucleic acid present in
a biological specimen without any prior knowledge of the target sequence. The ability of sample
multiplexing using barcodes enables simultaneous sequencing of a large number of samples in a single
run. This strategy fully exploits HTS systems by increasing throughput while reducing sequencing
costs [16].
4. Challenges in High-Throughput DNA Sequencing
Sample collection, transporting, handling, and storage conditions can profoundly affect the
quality of the sample and thus sequencing results. The development of laboratory standard operating
procedures is critical to ensure high quality input material.
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While HTS provides the most broad-based, unbiased approach for the detection of known and
novel viral agents from biological samples, it also faces challenges related to sample preparation and
data analysis that impede widespread use of the technique. The sample preparation protocols for HTS
require the removal of host-derived sequences, which are present in the sample, in order to ensure that
the sequence reads are of viral rather than host origin. Additionally, the massive amount of sequence
information generated in HTS requires extensive support from bioinformatics experts, customized
bioinformatic tools and powerful computer clusters to efficiently and rapidly analyze the data.
The choice of a sample preparation protocol strictly depends on the nature of the biological
specimen. Because host nucleic acid is present in great abundance as compared to virus genetic material
in biological specimens, procedures such as the depletion of host background or the enrichment of
viral genomes is critical to ensure the threshold detection of a viral signature. This is particularly true
for complex clinical specimens such as tissue samples like brain [17]. Conversely, cell-free samples
such as CSF contain low levels of starting material and specimens should first be filtered or centrifuged
to reduce the volume of the sample and to maximize the isolation of nucleic acids [17].
Viral nucleic acids may be enriched using either subtractive or positive selection methods.
Host and non-viral templates can be reduced through filtration, ribosomal RNA subtraction, and
nuclease treatment [17–21]. Filtration is particularly useful for the analysis of fecal samples and has
become standard practice, irrespective of whether additional enrichment strategies are employed [21].
Ribosomal rRNA subtraction has the potential to remove 95% of the host RNA; however, this level
of efficiency is rarely achieved [20]. Nuclease treatment is the most powerful of the subtractive
methods [18]. The rationale in this approach is that viral nucleic acid should be protected within its
nucleocapsid. However, in the event that the viral template is not contained within a nucleocapsid,
it will be lost to analysis. Thus, we cannot detect intracellular viral RNA using nuclease treatment.
The systematic analysis of extensive sequence data requires customized bioinformatic tools as
well as powerful computers. Genomic footprints of viruses are detected using Basic Local Alignment
Search Tool (BLAST) programs that compare sequences obtained by sequencing to those present in a
reference database. This sequence-based approach relies on the concept that new viruses will share
homology with known viruses.
The pipeline starts with the trimming of raw sequence reads to remove the adapter sequences
from the reads. Sequences are then filtered to eliminate low-complexity reads and repetitive sequences.
The dataset is further enriched for potential viral sequences by removing contaminating sequence
reads derived from host and bacterial sequences, followed by the clustering of redundant sequences.
The remaining sequences are further assembled into contiguous sequences and compared to the
GenBank databases at the nucleotide (BLASTN) and to the non-redundant protein sequences (nr)
database from NCBI (http://www.ncbi.nlm.nih.gov) using tBLASTx and BLASTx.
5. VirCapSeq-VERT
More recently, a positive selection method analogous to exon capture for viruses has been
established for viral diagnosis and discovery (VirCapSeq-VERT) [22]. The approach entails enriching
for relevant targets prior to analysis using probes that represent genomic sequences of known viruses.
VirCapSeq-VERT has been shown to have sensitivity similar to PCR and is less cumbersome than
enrichment by filtration and nuclease treatment [22].
The system employs approximately 2 million biotinylated oligonucleotide probes designed to
bind to the coding sequences of all viral taxa known to infect vertebrates at intervals of 50–100 nt.
Libraries prepared from random primed cDNA are hybridized with the biotinylated VirCap probes.
Streptavidin magnetic beads are added to trap biotinylated probes and their complementary library
components. After magnetic capture and washing, nucleic acid is released from the beads and subjected
to post-hybridization PCR prior to sequencing (Figure 1). Demultiplexed filtered reads are compared
by BLASTn to reference databases to remove the host background, assembled and then subjected
to a homology search in GenBank nucleotide and protein databases. This method yields a 100- to
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10,000-fold increase in viral reads from serum, blood, feces, saliva, and tissue homogenates compared to
conventional Illumina sequencing using established virus enrichment procedures, including filtration,
nuclease treatments, and RiboZero rRNA subtraction. This reduces the number of reads required per
sample from approximately 200 M to 5 M and streamlines bioinformatic analysis. VirCapSeq-VERT
has a limit of detection comparable to that of agent-specific real-time PCR.
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A potential confounding factor is that VirCapSeq-VERT may not detect entirely new viruses;
however, the likelihood of missing a virus that causes encephalitis is low because probe nucleic acid
homology to target is not as stringent as PCR; the entire genomic sequence of each virus is accessible
for capture and databases and probe libraries are continuously updated.
6. Microbial Contamination in HTS
The introduction of contaminating microbial sequences during the experimental process will lead
to false-positive findings and erroneous data interpretation [23–26]. It may also be a confounding
factor in the assessment of complex clinical samples such as tissue samples, cell-free samples, and
samples where an agent is generally present at low levels [23].
The identification of bona fide microbial contaminations may be identified by systematically
processing and sequencing a mock library preparation and a control sample in parallel with the
experimental samples. Additionally, the use of a repository of contaminating sequences may help in
some cases alleviate the effects of contamination by computationally excluding them from downstream
analysis. Importantly, any microbial signature identified by HTS needs to further be validated in the
original sample by specific PCR assays based on newly identified microbial genome sequences.
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A suggested flow chart for the laboratory investigation of unexplained viral encephalitis is shown
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real-time PCR. These as ays can be completed in a few hours and have the potential to detect less
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We typically r s rve one for a houseke ping gene (to ensure the prese ce of a nucleic acid template
in the sample as well as the integrity of the assay) and use the remai ing four for microbial targets.
By ssembling sev ral panels, we can rapidly test for the presence of 20 or more agents [27].
The presence of a signal provides an initial guide for th rapy; however, CSF s ould b retested to
ensure the validity of a finding. Cell counts and differential cell counts, as well as protein and glucose
measur s may be helpful; nonetheles , we proceed with comprehensiv molecular analys s until a
specific diagnosis is achieved, irrespective f whether the pattern is more consistent with bact rial or
viral infection. Where PCR fails to implicat an agent, we move t high-throughput sequencing of
CSF. High-throughput sequencing techniques have the pot ntial to detect nucleic acids that r present
viruses, bacteria, fu gi, or parasit s. However, the method is less sensitive than the analysis of libraries
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(bacteria) [28], internal tr nscribed spacer (ITS, fungi) region amplification [29,30], or selection using
biotinylated probes to viruses (VirCapSeq-VERT). In laboratories where sequenci g is routine, the time
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required from sample receipt to bioinformatics analysis is less than 72 h. Where high-throughput
sequencing of CSF fails, we recommend proceeding directly to brain biopsy; however, an alternative
strategy is to search other sites and samples including the oropharynx (oral swabs), gastrointestinal
tract (feces), urine, or blood for the presence of potential pathogens that might have metastasized in
the brain.
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9. Causal Relationship to Disease
This last point reinforces the notion that the identification of viral sequences in clinical material is
not necessarily the same as showing a causal association between the virus and the neurological disease.
Such an association is easiest to make when the infectious agent has been isolated at an appropriate site
during the course of active disease. However, access to specimens such as brain biopsy is generally not
available and the only surrogate specimen available for analysis is CSF. The possibility always exists
that the novel virus identified may play no role in disease pathogenesis and represents an irrelevant
co-infection. We must always consider and control for the possibility of sample contamination,
a particular hazard with PCR (especially nested-PCR). Nevertheless, identification of a virus in a
case of presumed viral encephalitis would normally be construed as strong evidence of causation
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unless there was additionally strong evidence to suggest either accidental contamination during the
procedure or an irrelevant co-existing infection.
Since CSF is normally acellular and sterile, clear evidence of a microbial signature in CSF merits
strong consideration as a candidate pathogen. Failure to detect a viral agent in a CNS disease
such as viral encephalitis may reflect the absence of its molecular footprint at the time of sampling.
Notwithstanding these caveats, investigating CNS infections of unknown etiology using unbiased
HTS or VirCapSeq-VERT may identify the complete spectrum of causative agents associated with
encephalitis. Further, early recognition of the causative agent of unexplained encephalitis cases could
enable specific interventions that reduce illness and death and facilitate the recognition of outbreaks
that threaten public health.
10. Conclusions
Despite the progress that has been made with both classical virological and molecular biological
technologies in identifying the numerous causes of viral encephalitis, there is an increasing need for
better tools and new approaches for detecting both genuinely novel pathogens in such patients and
determining new manifestations of known pathogens, including viruses. In evaluating the results of
different studies, it is crucial to have uniform clinical and diagnostic criteria for establishing a definite
diagnosis of viral encephalitis. There is not a standardized algorithm for the molecular investigation
of unexplained encephalitis, though general guidelines for the investigation and management of
suspected viral encephalitis are now available [6,38]. Problems of contamination of tissues during
procedures, and adequate sensitivity and specificity continue to influence the interpretation of CSF
PCR. High-throughput sequencing technology has added a new and exciting dimension to our ability
to unambiguously identify the presence of novel viruses in patients with encephalitis of unknown
cause. Nevertheless, caution must always be exercised in assuming a direct cause and effect relation
between the newly identified virus and the neurological infection. The extent to which the anticipated
identification of novel viruses in viral encephalitis will lead to direct and early improvement in new
therapies and a better prognosis for such individuals is difficult to predict. However, these advanced
genomic techniques certainly have great potential in improving the diagnosis and management of
patients with a range of viral infections [39]. It is possible that the initial benefits may be more applicable
to immunocompromised individuals with CNS viral infections, in whom novel viral infections may be
easier to detect.
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